New Data on Metabolon's Prediabetes Test to be Featured in Two Poster Presentations at ADA Conference

Quantose IGT Studied as Convenient Alternative to Oral Glucose Tolerance Test

        Print
| Source: Metabolon, Inc.

RESEARCH TRIANGLE PARK, N.C., June 12, 2014 (GLOBE NEWSWIRE) -- Metabolon, Inc., a global leader in metabolomics, announces that two posters highlighting data from studies using its Quantose IGTTM prediabetes test will be presented at the American Diabetes Association's (ADA) 74th Scientific Sessions to be held June 13-17 at the Moscone Center in San Francisco.

The Quantose IGT test is designed to easily differentiate impaired glucose tolerance (IGT) from normal glucose tolerance. Traditionally, the oral glucose tolerance test (OGTT) has been used to identify impaired tolerance, but has fallen out of favor because it requires multiple blood draws over several hours. In contrast, the Quantose IGT test requires only a single fasting blood draw.

Many primary care physicians currently screen for prediabetes using one of two methods: the fasting plasma glucose (FPG) test, which provides current glycemic status, and/or measuring hemoglobin A1c, which reflects average blood glucose levels over several months.

"Although patients may appear to have normal glucose tolerance based on FPG or hemoglobin A1c results, Quantose IGT can detect underlying prediabetes and suggest further testing or immediate intervention. Knowledge of prediabetes allows physicians to begin monitoring and treating patients earlier, as recommended in the 2014 ADA Standards of Medical Care in Diabetes," stated Eric Button, Senior Vice President of Diagnostics at Metabolon. "We've developed Quantose IGT to identify impaired glucose tolerance through a single fasting blood draw, which is more convenient than an OGTT for physicians and patients."

Results from the RISC (Relationship between Insulin Sensitivity and Cardiovascular disease) and Vhi (Voluntary Health Insurance Board, Ireland) cohorts will be presented by investigators from the University of Pisa School of Medicine (Pisa, Italy), Vhi Healthcare (Dublin, Ireland) and Metabolon, as follows:

Metabolomic Characterization of Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) – Abstract 1372-P

Sunday, June 15, 2014, 12:00 - 2:00 p.m. Pacific Time

Hall D (North Building)

Novel Metabolite Models that Distinguish Impaired Glucose Tolerance (IGT) from Normal Glucose Tolerance (NGT) – Abstract 1381-P

Sunday, June 15, 2014, 12:00 - 2:00 p.m. Pacific Time

Hall D (North Building)

About Quantose IGT

Quantose IGT is a laboratory-developed test (LDT) that reflects the degree of impaired glucose tolerance in an individual. Impaired glucose tolerance is a core metabolic defect in dysglycemia and, as such, is a known risk factor for prediabetes. Quantose IGT may be used as an alternative to an OGTT or to identify patients who may be candidates for an OGTT.

About Metabolon

Metabolon, Inc. is a world-leading, commercial-stage metabolomics company whose expertise is embraced by companies in the pharmaceutical, biotechnology, consumer products, agricultural, pet care and nutrition industries, as well as government and academic institutions. Founded in 2000, the company is pioneering the emerging field of biochemical pathway analysis for biomarker discovery and development of innovative, cost-effective diagnostic tests. Our technology is the product of more than 12 years of R&D and is powered by our proprietary MetabolyzerTM software. Our metabolytics business has conducted more than 3,000 collaborative studies with over 600 clients to identify diseases, discover biomarkers, and better understand

complex biological processes. Our diagnostics business consists of tests that enable early detection for the effective prevention of obesity-related diseases and monitoring tests for cancer. For more information, please visit www.metabolon.com.

Cautionary Note about Forward-Looking Statements

The materials provided herein that are not historical facts are or might constitute projections and other forward-looking statements regarding future events that involve substantial risks, uncertainties and assumptions. If any of these risks or uncertainties materialize, or if any of these assumptions prove incorrect, the results of Metabolon could differ materially from the results expressed or implied by any forward-looking statements. The risks, uncertainties and assumptions referred to above include, but are not limited to: the uncertainties inherent in biochemical research and development; decisions by regulatory authorities regarding whether and when to approve diagnostic tests; our distributors' ability to successfully commercialize and market both new and existing products; governmental laws and regulations affecting health care, including regarding access, pricing and reimbursement of diagnostic tests; the strength of our intellectual property portfolio; our history of losses; whether we are able to achieve or sustain profitability; our highly competitive industry; our ability to compete effectively; security and privacy risks; and our ability to continue to innovate and provide products and services that are useful to our clients, among other risks, uncertainties and assumptions.

Robin Fastenau
Vice President, Corporate Marketing & Communications
919.595.2201